1 hour ago
2
The archetypal nationalist offering (IPO) of Suraksha Diagnostic Limited, a healthcare assemblage institution that offers pathology, radiology investigating and aesculapian consultancy services, volition beryllium unfastened for subscription connected November 29, 2024, and investors besides use for pre-application up of opening. The healthcare institution has fixed a terms set for the IPO betwixt Rs 420 and Rs 441 with a look worth of Rs 2 per share. It volition beryllium concluded successful the adjacent period i.e. December 3, 2024.
The contented size of the Suraksha Diagnostic Limited IPO is Rs 846.25 crore which comprises an connection for merchantability (OFS) of 1.91 crore shares, with nary caller contented component. Investors tin bid for a minimum batch size of 34 shares and successful multiples thereof. The allocation ratio for the contented is acceptable astatine 50 per cent, 35 per cent, and 15 per cent for Qualified Institutional Buyers (QIBs), retail investors, and Non-Institutional Investors (NIIs), respectively.
Suraksha Diagnostic Limited IPO: BRLMS
The IPO is being managed by respective starring wealthiness absorption companies similar ICICI Securities, Nuvama Wealth Management, and SBI Capital Markets.
Suraksha Diagnostic Limited IPO: Registrar
The authoritative registrar of Suraksha Diagnostic Limited IPO is KFin Technologies.
Suraksha Diagnostic Limited IPO: Important dates
As mentioned earlier the IPO volition unfastened for subscription connected Friday, November 29, 2024, and adjacent connected Tuesday, December 3, 2024. The ground of allotment volition beryllium finalised connected Wednesday, December 4, 2024. The banal volition debut connected the exchanges - BSE and NSE - connected Friday, December 6, 2024.
Analysts from 2 home brokerages outlined that the precocious terms set of the Suraksha Diagnostic Limited IPO is astatine premium pricing connected the ground of earnings. Know present what they say:
Should you use for Suraksha Diagnostic IPO? Here's what analysts recommend
According to SBI Securities' analysts, the precocious terms set of Rs 441 underscores the premium attributed to the company’s presumption arsenic an integrated diagnostics provider, offering a one-stop solution for pathology, radiology, and aesculapian consultation services.
Meanwhile, adjacent highlighting that the valuation metrics suggest premium pricing for the IPO, different home brokerage, Bajaj Broking has recommended to investors that use for a semipermanent horizon.
Here is simply a summary of the different healthcare diagnostic companies on with P/E, RoE, income and more:
| Particulars (in cr) | Suraksha Diagnostic | Dr Lal PathLabs | Metropolis Healthcare | Thyrocare Technologies | Vijaya Diagnostic |
| CMP (Rs) | 441 (upper terms band) | 3082 | 2160 | 1020 | 1164 |
| Sales | 218.7 | 2226.6 | 1207.7 | 571.9 | 547.8 |
| EBITDA | 70.1 | 609.3 | 282.6 | 137.4 | 220.9 |
| Net Profit | 23.1 | 362.3 | 128.5 | 96 | 119.6 |
| Mkt Cap. | 2296.8 | 25755 | 11071 | 5403 | 11946 |
| Enterprise Value | 2250.4 | 25008 | 11000 | 5363 | 11873 |
| EBITDA Margin (%) | 32 | 27.4 | 23.4 | 24 | 40.3 |
| Net Profit Margin (%) | 10.6 | 16.3 | 10.6 | 16.8 | 21.8 |
| P/E (x) | 96.1 | 71.9 | 86.6 | 76.3 | 100.3 |
| EV/EBITDA (x) | 32.1 | 41 | 38.9 | 39 | 53.7 |
| RoE (%) | 13.3 | 19.6 | 11.7 | 19.7 | 18.2 |
| ROCE (%) | 21.8 | 24.1 | 17.2 | 17.2 | 24.9 |
| EV/Sales | 5.1 | 8.1 | 5.1 | 9.4 | 21.7 |
.png "indianexpress.")
.png "khaleejtimes")
.png "arabnews")
.png "gulfnews"){kind=logo}
English (US) · 
Hindi (IN) ·